Attention is focusing on the procedure for registering insurance benefits for another one-shot gene therapy. According to related industries, discussions are underway to register the benefit of Novartis' Inherited Retinal Dystrophy (IRD) treatment Luxturna.

As the application for benefits was submitted in September last year, it remains to be seen whether it will be possible to announce the HIRA's drug benefit evaluation committee within the first half of the year. Depending on the speed of the procedure, Luxturna can enter the benefit right within this year. Luxturna restores function by replacing the deficient and defective RPE65 gene, one of the causes of IRD, with a normal gene only once administere